search
Back to results

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

Primary Purpose

Time Restricted Eating, Obesity, Weight Loss

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Time restricted eating
Calorie Restriction
Sponsored by
University of Illinois at Chicago
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Time Restricted Eating

Eligibility Criteria

45 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. 45-65 years old, BMI 30-49.99 kg/m2
  2. At elevated risk for CRC based on the following criteria: In the past 5 years, 3 or more adenomatous polyps or an adenomatous polyp >1 cm, a well-accepted definition of increased risk
  3. Are up to date with CRC screening.
  4. Prediabetic or insulin resistant (fasting glucose 100-125mg/dl or HOMA-IR>2)

Exclusion Criteria:

  1. Have a history of renal disease, autoimmune disorders, immunodeficiency, malabsorptive disorder, significant gastrointestinal and hepatic disease, surgical change in gastrointestinal anatomy, severe ischemic heart disease, severe pulmonary disease, severe mental health disorder, eating disorder, or bariatric surgery;
  2. Abuse alcohol (> 50 grams/day), illicit drugs (other than self-reported marijuana use), or use combustible tobacco;
  3. Have controlled type 2 diabetes or undiagnosed uncontrolled diabetes based on hemoglobin A1c (HbA1c) > 9.0%;
  4. Have a history of cancer treatment within the past 12 months, CRC, genetic predisposition to CRC (e.g., Lynch syndrome);
  5. Have a baseline body weight > 450 lbs (weight limitation of the DXA);
  6. Are on a weight loss diet or actively involved in a formal weight loss program (e.g., Weight Watchers);
  7. Are not weight stable for 3 months prior to the study (weight gain or loss > 4 kg);
  8. Are unable to keep a food diary for 7 consecutive days during screening;
  9. Are night shift workers;
  10. Are pregnant or trying to get pregnant;
  11. Are taking drugs that influence study outcomes (weight loss medications);
  12. Are perimenopausal or have an irregular menstrual cycle (menses that does not appear every 27-32 days).
  13. Are non-English speaking
  14. Are taking anticoagulant medications or medications with endoscopic risk
  15. Are taking antivirals or immunosuppressant medications

Sites / Locations

  • University of Illinois at ChicagoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Active Comparator

No Intervention

Arm Label

Time Restricted Eating (TRE)

Calorie Restriction (Cal-R)

Control

Arm Description

During the active weight loss period, the TRE group will be instructed to eat ad libitum from 12:00pm - 8:00pm daily and fast from 8:00pm - 12:00pm. During the 8-h eating window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, participants will be encouraged to drink plenty of water and may consume energy-free beverages, such as black tea or coffee. TRE subjects will meet with the TRE dietitian for 30 minutes at the start of the intervention to review instructions and goals, and then every week throughout the active weight loss period to review intervention adherence. At the beginning of the maintenance phase, total energy needs will be reassessed. Subjects will be instructed to main their body weight by consuming meals in an extended 10-h eating window every day and water fast between 8pm and 10 am, respectively.

Cal-R subjects will be instructed to restrict energy intake by 25% of their baseline total energy expenditure (TEE) daily. Subjects will meet with a study dietitian for a 60-min one-on-one session to develop individualized weight loss meal plans to help them adhere to their calorie restriction goal. Meal plans will include portion sizes and food lists that are consistent with their food preferences and prescribed calorie levels for weight loss. Food scales will be provided to help with food portioning. Cal-R subjects will meet with the dietitian every week throughout the weight loss period to review intervention adherence and modify the meal plans as needed. Subjects will be asked to maintain their baseline level of physical activity. At the beginning of the weight maintenance phase, total energy needs will be reassessed.

Controls will be instructed to maintain their weight throughout the 12 m trial and to not change eating or physical activity habits. Controls will not receive dietary counseling. Controls will visit the research center monthly for outcome measurements.

Outcomes

Primary Outcome Measures

Weight change (% kg)
Body weight in kg

Secondary Outcome Measures

Total and regional body fat composition and distribution
Total and regional body fat composition and distribution will be measured via whole body DEXA scan
Intervention adherence
Measured through electronic diet records and 24 hour dietary recalls
Fasting plasma glucose
From fasting venous blood measured by a commercial lab
Plasma cytokines TNF-α, IL-6, IL1-β, and IL-10, %
Multiplex ELISA
Plasma 8-isoprostane
ELISA
Colonic mucosa gene expression profiling
Commercially available targeted transcriptomics platform
Ki-67, proliferation
Healthy colonic mucosa, immunohistochemistry
c-caspase-3, Bax, apoptosis
Healthy colonic mucosa, immunohistochemistry,
CD3, CD163, pIKKa/b, tissue markers of inflammation
Healthy colonic mucosa, immunohistochemistry
Weight maintenance (% kg)
Maintenance of weight loss
Fasting plasma insulin
From fasting venous blood measured at a commercial lab
HOMA-IR
calculated from fasting glucose and insulin using a standard formula
Gut Microbiome
Shotgun metagenomics
Fecal Metabolites
Untargeted Metabolomics

Full Information

First Posted
September 29, 2021
Last Updated
June 27, 2023
Sponsor
University of Illinois at Chicago
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT05114798
Brief Title
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
Official Title
Effects of Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers Among Adults With Obesity
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 17, 2022 (Actual)
Primary Completion Date
July 2026 (Anticipated)
Study Completion Date
September 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Illinois at Chicago
Collaborators
National Cancer Institute (NCI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Approximately 42% of American adults are obese, and this condition is strongly related to the development of colorectal cancer. Innovative lifestyle strategies to treat obesity and reduce colorectal cancer risk are critically needed. This research will demonstrate that time-restricted eating, a type of intermittent fasting, is an effective therapy to help obese individuals reduce and control their body weight and prevent the development of colorectal cancer.
Detailed Description
Approximately 42% of the U.S. adult population is obese and data suggests that persons with obesity are at a 30% greater risk of developing colorectal cancer (CRC). Therefore, efficacious approaches to preventing and treating obesity will have significant effects on CRC incidence in the U.S. Although calorie restriction through lifestyle intervention is the most common approach to treat obesity, clinically meaningful weight loss is difficult to achieve via this method due to low adherence with calorie monitoring, indicating a need for innovation. Time-restricted eating, a type of intermittent fasting, has been shown in animals to impart cancer protective effects including lower body weight, decreased systemic inflammation, and improved glucose metabolism. Time-restricted eating is where individuals are asked to consume all their food for the day within a specified time frame, and water fast for the remaining hours of the day. We recently performed two short-term (≤12-weeks) pilot studies of time-restricted eating to evaluate its safety and preliminary efficacy on body weight and chronic disease risk markers in adults with obesity. Our results show the intervention is a safe and acceptable approach to weight loss among obese adults. Moreover, time-restricted eating produced approximately 3% weight loss from baseline and reductions in systolic blood pressure, oxidative stress and insulin resistance. Although these pilot findings show promise for time-restricted eating as an effective tool for CRC risk reduction among obese individuals, these data still require confirmation by a well powered longer-term clinical trial. The present proposal aims to implement a 12-month (6-month intervention, 6-month maintenance) controlled, parallel arm trial among 255 obese adults (45-70 years old) who have had a colonoscopy. Subjects will be randomized to 1 of 3 groups: 1) 8-hour time-restricted eating (daily ad libitum food intake from 12pm - 8pm), 2) Calorie restriction (daily 25% calorie restriction), or 3) Control (daily ad libitum food intake, no meal timing restrictions) to compare the effects on: (1) Body weight, body composition, and intervention adherence; (2) Circulating metabolic, inflammation, and oxidative stress-related biomarkers; (3) Colonic mucosal gene expression profiles and mucosal inflammation, DNA damage and cellular growth; and (4) maintenance of benefits on body weight/composition and CRC markers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Time Restricted Eating, Obesity, Weight Loss, Colorectal Cancer

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Subjects will be randomized by the data manager, by way of a stratified random sample in 1:1:1 ratio. The sample frame will be divided into strata based on BMI, sex, and age. Subjects from each stratum, will then be randomized to 1 of 3 groups: 1) TRE, 2) Cal-R, or 3) Control.
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
255 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Time Restricted Eating (TRE)
Arm Type
Experimental
Arm Description
During the active weight loss period, the TRE group will be instructed to eat ad libitum from 12:00pm - 8:00pm daily and fast from 8:00pm - 12:00pm. During the 8-h eating window, there will be no restrictions on types or quantities of foods consumed. During the fasting period, participants will be encouraged to drink plenty of water and may consume energy-free beverages, such as black tea or coffee. TRE subjects will meet with the TRE dietitian for 30 minutes at the start of the intervention to review instructions and goals, and then every week throughout the active weight loss period to review intervention adherence. At the beginning of the maintenance phase, total energy needs will be reassessed. Subjects will be instructed to main their body weight by consuming meals in an extended 10-h eating window every day and water fast between 8pm and 10 am, respectively.
Arm Title
Calorie Restriction (Cal-R)
Arm Type
Active Comparator
Arm Description
Cal-R subjects will be instructed to restrict energy intake by 25% of their baseline total energy expenditure (TEE) daily. Subjects will meet with a study dietitian for a 60-min one-on-one session to develop individualized weight loss meal plans to help them adhere to their calorie restriction goal. Meal plans will include portion sizes and food lists that are consistent with their food preferences and prescribed calorie levels for weight loss. Food scales will be provided to help with food portioning. Cal-R subjects will meet with the dietitian every week throughout the weight loss period to review intervention adherence and modify the meal plans as needed. Subjects will be asked to maintain their baseline level of physical activity. At the beginning of the weight maintenance phase, total energy needs will be reassessed.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Controls will be instructed to maintain their weight throughout the 12 m trial and to not change eating or physical activity habits. Controls will not receive dietary counseling. Controls will visit the research center monthly for outcome measurements.
Intervention Type
Behavioral
Intervention Name(s)
Time restricted eating
Intervention Description
daily ad libitum food intake, 8-h 12pm - 8pm, 6 m active weight loss phase; 10-h 10am-8pm, 6 m maintenance phase
Intervention Type
Behavioral
Intervention Name(s)
Calorie Restriction
Intervention Description
daily 25% calorie restriction, 6 m active weight loss phase; 100% energy needs, 6 m maintenance phase
Primary Outcome Measure Information:
Title
Weight change (% kg)
Description
Body weight in kg
Time Frame
Baseline to month 6
Secondary Outcome Measure Information:
Title
Total and regional body fat composition and distribution
Description
Total and regional body fat composition and distribution will be measured via whole body DEXA scan
Time Frame
Baseline, 6 month and 12 month
Title
Intervention adherence
Description
Measured through electronic diet records and 24 hour dietary recalls
Time Frame
Monthly, through month 6
Title
Fasting plasma glucose
Description
From fasting venous blood measured by a commercial lab
Time Frame
Baseline, month 3, month 6, month 9, month 12
Title
Plasma cytokines TNF-α, IL-6, IL1-β, and IL-10, %
Description
Multiplex ELISA
Time Frame
Baseline, month 3, month 6, month 9, month 12
Title
Plasma 8-isoprostane
Description
ELISA
Time Frame
Baseline, month 3, month 6, month 9, month 12
Title
Colonic mucosa gene expression profiling
Description
Commercially available targeted transcriptomics platform
Time Frame
Baseline, month 6
Title
Ki-67, proliferation
Description
Healthy colonic mucosa, immunohistochemistry
Time Frame
Baseline, month 6
Title
c-caspase-3, Bax, apoptosis
Description
Healthy colonic mucosa, immunohistochemistry,
Time Frame
Baseline, month 6
Title
CD3, CD163, pIKKa/b, tissue markers of inflammation
Description
Healthy colonic mucosa, immunohistochemistry
Time Frame
Baseline, month 6
Title
Weight maintenance (% kg)
Description
Maintenance of weight loss
Time Frame
Month 6 to month 12
Title
Fasting plasma insulin
Description
From fasting venous blood measured at a commercial lab
Time Frame
Baseline, month 3, month 6, month 9, month 12
Title
HOMA-IR
Description
calculated from fasting glucose and insulin using a standard formula
Time Frame
Baseline, month 3, month 6, month 9, month 12
Title
Gut Microbiome
Description
Shotgun metagenomics
Time Frame
Baseline, month 3 and month 6
Title
Fecal Metabolites
Description
Untargeted Metabolomics
Time Frame
Baseline, month 3 and month 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 45-70 years old, BMI 30-49.99 kg/m2 Are up to date with CRC screening. Exclusion Criteria: Have a history of renal disease, autoimmune disorders, immunodeficiency, malabsorptive disorder, significant gastrointestinal and hepatic disease, surgical change in gastrointestinal anatomy, severe ischemic heart disease, severe pulmonary disease, severe mental health disorder, eating disorder, or bariatric surgery; Abuse alcohol (> 50 grams/day), illicit drugs (other than self-reported marijuana use), or use combustible tobacco; Have controlled type 2 diabetes or undiagnosed uncontrolled diabetes based on hemoglobin A1c (HbA1c) > 9.0%; Have a history of cancer treatment within the past 12 months, CRC, genetic predisposition to CRC (e.g., Lynch syndrome); Have a baseline body weight > 450 lbs (weight limitation of the DXA); Are on a weight loss diet or actively involved in a formal weight loss program (e.g., Weight Watchers); Are not weight stable for 3 months prior to the study (weight gain or loss > 4 kg); Are unable to keep a food diary for 7 consecutive days during screening; Are night shift workers; Are pregnant or trying to get pregnant; Are taking drugs that influence study outcomes (weight loss medications); Are perimenopausal or have an irregular menstrual cycle (menses that does not appear every 27-32 days). Are non-English speaking Are taking anticoagulant medications or medications with endoscopic risk Are taking antivirals or immunosuppressant medications Don't have regular access to an email address and computer/smartphone/tablet Are currently following a diet that requires fasting on a weekly basis Currently eat for less than 10 hours of the day (determined by asking participants what time they start and stop eating on a usual day)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lisa Tussing-Humphreys, PhD, MS, RD
Phone
312-355-5521
Email
ltussing@uic.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Krista Varady, PhD
Phone
312-996-7897
Email
varady@uic.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lisa Tussing-Humphreys, PhD, MS, RD
Organizational Affiliation
University of Illinois at Chicago
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Illinois at Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lisa Tussing-Humphreys
Phone
312-355-5521
Email
ltussing@uic.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers

We'll reach out to this number within 24 hrs